Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share:

	Three months ended June 30,						Six months ended June 30,
	2018			2017			2018			2017
Numerator:
Net loss applicable to common stockholders, basic and diluted	$	(7,978	)	$	(5,507	)	$	(15,877	)	$	(13,809	)

Denominator:
Weighted-average number of shares, basic and diluted		60,621			25,515			60,386			23,717

Net loss per share, basic and diluted	$	(0.13	)	$	(0.22	)	$	(0.26	)	$	(0.58	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
Options to purchase common stock		2,916		2,537		2,916		2,537
Restricted stock		78		-		78		-
Warrants for common stock		3,396		5,092		3,396		5,092
Total common stock equivalents		6,390		7,629		6,390		7,629